The effect of ceruloplasmin on experimental infection with influenza virus APR 8/34 (H0N1) in the mouse.
Ceruloplasmin administered in different variants confers on mice protection against experimental infection with influenza virus APR 8/34 (H0N1). The optimal variants are: inoculation of an extemporaneous virus-ceruloplasmin mixture, followed by two additional ceruloplasmin applications (which confers maximum protection against initial infection) and the administration of ceruloplasmin prior to virus inoculation (which assures the highest resistance to challenge infection).
D000818:Animals; D002570:Ceruloplasmin / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D009975:Orthomyxoviridae / Q000187:drug effects* / Q000472:pathogenicity; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*
D002570:Ceruloplasmin